M. van de Laar

1.0k total citations · 1 hit paper
16 papers, 525 citations indexed

About

M. van de Laar is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, M. van de Laar has authored 16 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Rheumatology, 4 papers in Genetics and 3 papers in Hematology. Recurrent topics in M. van de Laar's work include Rheumatoid Arthritis Research and Therapies (10 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). M. van de Laar is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (10 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). M. van de Laar collaborates with scholars based in Netherlands, France and United Kingdom. M. van de Laar's co-authors include Marco Matucci‐Cerinic, David T. Felson, E. Martín‐Mola, H Awada, M. Hochberg, Maxime Dougados, Florence Tubach, D. van der Heijde, Philippe Ravaud and N. Hajjaj‐Hassouni and has published in prestigious journals such as Annals of the Rheumatic Diseases, International Journal of Epidemiology and Osteoarthritis and Cartilage.

In The Last Decade

M. van de Laar

16 papers receiving 511 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study

2012 316 citations Florence Tubach, Philippe Ravaud et al. Arthritis Care & Research profile →

Peers

Countries citing papers authored by M. van de Laar

Since Specialization

Citations

This map shows the geographic impact of M. van de Laar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. van de Laar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. van de Laar more than expected).

Fields of papers citing papers by M. van de Laar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. van de Laar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. van de Laar. The network helps show where M. van de Laar may publish in the future.

Co-authorship network of co-authors of M. van de Laar

This figure shows the co-authorship network connecting the top 25 collaborators of M. van de Laar. A scholar is included among the top collaborators of M. van de Laar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. van de Laar. M. van de Laar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	POS0830 BARICITINIB VERSUS TNF-INHIBITORS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CSDMARDS: 12 WEEKS RESULTS OF A PRAGMATIC, MULTICENTER, OPEN LABEL, NONINFERIORITY TRIAL 2023 ·Annals of the Rheumatic Diseases ·(unknown), Peter M. ten Klooster, Danyta I. Tedjo, (unknown), M. van de Laar	1
2	Increased IL-6 receptor expression and signaling in ageing cartilage can be explained by loss of TGF-β-mediated IL-6 receptor suppression 2021 ·Osteoarthritis and Cartilage ·(unknown), (unknown), A. van Caam, M. van de Laar, Henk M. van Beuningen, Marije I. Koenders, Peter L. E. M. van Lent, P.M. van der Kraan, Fons A. J. van de Loo, E.N. Blaney Davidson	13
3	Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison 2020 ·RMD Open ·Bruno Fautrel, Baojin Zhu, Peter C. Taylor, M. van de Laar, Paul Emery, Francesco De Leonardis, (unknown), Claudia Nicolay, Zbigniew Kadziola, Inmaculada de la Torre, Roy Fleischmann	27
4	OP0257-PARE USING PATIENT HEALTH LITERACY PROFILES TO IDENTIFY SOLUTIONS TO CHALLENGES FACED IN RHEUMATOLOGY CARE 2020 ·Annals of the Rheumatic Diseases ·(unknown), Polina Putrik, Jany Rademakers, M. van de Laar, Harald E. Vonkeman, Marc R. Kok, (unknown), Sofía Ramiro, Maarten de Wit, Richard H. Osborne, Roy Batterham, Rachelle Buchbinder, Annelies Boonen	4
5	THU0579 “EVOLVING THE MANAGEMENT OF RA” PROGRAMME: EDUCATIONAL TOOLS TO SUPPORT DAILY PRACTICE 2020 ·Annals of the Rheumatic Diseases ·Gerd R Burmester, (unknown), Neil Betteridge, (unknown), Bernard Combe, Patrick Durez, (unknown), Bruno Fautrel, Annamaria Iagnocco, Carlomaurizio Montecucco, Mikkel Østergaard, Sofía Ramiro, Andrea Rubbert‐Roth, Tanja Stamm, Zoltán Szekanecz, Peter C. Taylor, M. van de Laar	3
6	The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries 2017 ·Lara D. Veeken ·Sarah Hewlett, John Kirwan, Christina Bode, Fiona Cramp, Loreto Carmona, Emma Dures, Matthias Englbrecht, Jaap Fransen, Rosemary Greenwood, (unknown), M. van de Laar, Anna Moltó, Joanna Nicklin, Ingemar F. Petersson, (unknown), Georg Schett, Laure Gossec	36
7	THU0081 Differences in patient-reported outcomes between baricitinib and comparators among patients with rheumatoid arthritis who achieved low disease activity or remission 2017 ·Annals of the Rheumatic Diseases ·Bruno Fautrel, M. van de Laar, Bruce Kirkham, Rieke Alten, Regina Cseuz, Sarita van Geest, Baojin Zhu, Francesco De Leonardis, Peter C. Taylor	2
8	FRI0367 Fatigue is an Internationally Valid Concept: The Bristol RA Fatigue Multi-Dimensional Questionnaire (BRAF-MDQ) in 6 EU Countries 2015 ·Annals of the Rheumatic Diseases ·Sarah Hewlett, J. Nicklin, John Kirwan, Fiona Cramp, Emma Dures, Rosemary Greenwood, Jack Fransen, Matthias Englbrecht, Georg Schett, Ingemar F. Petersson, (unknown), Loreto Carmona, (unknown), (unknown), Christina Bode, M. van de Laar, Laure Gossec	1
9	OP0299-HPR The Evaluation of A Patient Decision AID for Anti-Rheumatic Drugs 2014 ·Annals of the Rheumatic Diseases ·(unknown), Constance H.C. Drossaert, Erik Taal, M. van de Laar	2
10	Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study breakdown → 2012 ·Arthritis Care & Research ·Florence Tubach, Philippe Ravaud, E. Martín‐Mola, H Awada, Nicholas Bellamy, Claire Bombardier, David T. Felson, N. Hajjaj‐Hassouni, M. Hochberg, I. Logeart, Marco Matucci‐Cerinic, M. van de Laar, D. van der Heijde, Maxime Dougados	316
11	SAT0481 Are TNF blocking agents associated with changes in work participation in patients with RA? 2012 ·Annals of the Rheumatic Diseases ·(unknown), Wietske Kievit, (unknown), (unknown), H.L.M. Brus, Jaap Fransen, M. van de Laar, Piet L. C. M. van Riel	2
12	THU0480-HPR Which factors are related to fatigue in rheumatoid arthritis? 2012 ·Annals of the Rheumatic Diseases ·Stephanie Nikolaus, Christina Bode, Erik Taal, M. van de Laar	1
13	Efficacy of combined porcine reproductive and respiratory syndrome virus and Mycoplasma hyopneumoniae vaccination in piglets 2010 ·Veterinary Record ·(unknown), (unknown), Marc Raes, M. van de Laar, (unknown), E. Thacker	11
14	Arthritis patients show long-term benefits from 3 weeks intensive exercise training directly following hospital discharge 2007 ·Lara D. Veeken ·(unknown), K.W. Drossaers-Bakker, Erik Taal, Johannes J. Rasker, Johanna C. M. Oostveen, (unknown), Frits G. J. Oosterveld, M. van de Laar	27
15	Prevalence and correlates of herpes simplex virus type 2 infection: evaluation of behavioural risk factors 1998 ·International Journal of Epidemiology ·M. van de Laar, Fabian Termorshuizen, Maria Słomka, (unknown), J M Ossewaarde, David Brown, R A Coutinho, J. van den Hoek	63
16	Components of health: an analysis in rheumatoid arthritis using quality of life questionnaires and clinical and laboratory variables. 1993 ·Annals of the Rheumatic Diseases ·(unknown), M. van de Laar, (unknown), (unknown)	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact